LONDON—Hematopoietic stem cells are not displaced and depleted by malignant cells in patients with acute myeloid leukaemia but merely put to sleep, according to research from London published in PNAS Early Edition. Professor John Gribben from Barts Cancer Institute in London discusses their finding and explains how this gives new opportunities for treating AML.
You may also like...
Active Surveillance Better for Which Renal Cell Cancers? 17 Apr, 2017 Gene expression and molecular pathways guide head and neck cancer therapies 24 Apr, 2013 Non Communicable Diseases: Crisis For Low And Middle Income Countries 12 Nov, 2011 ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 5 Jun, 2006
- Previous story Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia
- Next story Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014